913 related articles for article (PubMed ID: 25924065)
1. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
Shalapour S; Font-Burgada J; Di Caro G; Zhong Z; Sanchez-Lopez E; Dhar D; Willimsky G; Ammirante M; Strasner A; Hansel DE; Jamieson C; Kane CJ; Klatte T; Birner P; Kenner L; Karin M
Nature; 2015 May; 521(7550):94-8. PubMed ID: 25924065
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity.
Zhou J; Yang T; Liu L; Lu B
Mol Med Rep; 2017 Sep; 16(3):2868-2874. PubMed ID: 28677730
[TBL] [Abstract][Full Text] [Related]
3. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
4. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
5. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.
Shalapour S; Lin XJ; Bastian IN; Brain J; Burt AD; Aksenov AA; Vrbanac AF; Li W; Perkins A; Matsutani T; Zhong Z; Dhar D; Navas-Molina JA; Xu J; Loomba R; Downes M; Yu RT; Evans RM; Dorrestein PC; Knight R; Benner C; Anstee QM; Karin M
Nature; 2017 Nov; 551(7680):340-345. PubMed ID: 29144460
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.
De Sanctis F; Sandri S; Martini M; Mazzocco M; Fiore A; Trovato R; Garetto S; Brusa D; Ugel S; Sartoris S
Vaccine; 2018 Jun; 36(25):3708-3716. PubMed ID: 29752021
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.
Liu WM; Fowler DW; Smith P; Dalgleish AG
Br J Cancer; 2010 Jan; 102(1):115-23. PubMed ID: 19997099
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T cells swarm by homotypic chemokine signalling.
Galeano Niño JL; Pageon SV; Tay SS; Colakoglu F; Kempe D; Hywood J; Mazalo JK; Cremasco J; Govendir MA; Dagley LF; Hsu K; Rizzetto S; Zieba J; Rice G; Prior V; O'Neill GM; Williams RJ; Nisbet DR; Kramer B; Webb AI; Luciani F; Read MN; Biro M
Elife; 2020 Oct; 9():. PubMed ID: 33046212
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.
Diener KR; Woods AE; Manavis J; Brown MP; Hayball JD
Lab Invest; 2009 Feb; 89(2):142-51. PubMed ID: 19079323
[TBL] [Abstract][Full Text] [Related]
13. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.
Tauriello DVF; Palomo-Ponce S; Stork D; Berenguer-Llergo A; Badia-Ramentol J; Iglesias M; Sevillano M; Ibiza S; Cañellas A; Hernando-Momblona X; Byrom D; Matarin JA; Calon A; Rivas EI; Nebreda AR; Riera A; Attolini CS; Batlle E
Nature; 2018 Feb; 554(7693):538-543. PubMed ID: 29443964
[TBL] [Abstract][Full Text] [Related]
14. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells.
Lee HM; Timme TL; Thompson TC
Cancer Res; 2000 Apr; 60(7):1927-33. PubMed ID: 10766182
[TBL] [Abstract][Full Text] [Related]
15. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.
Ammirante M; Shalapour S; Kang Y; Jamieson CA; Karin M
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14776-81. PubMed ID: 25267627
[TBL] [Abstract][Full Text] [Related]
16. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Hodge JW; Garnett CT; Farsaci B; Palena C; Tsang KY; Ferrone S; Gameiro SR
Int J Cancer; 2013 Aug; 133(3):624-36. PubMed ID: 23364915
[TBL] [Abstract][Full Text] [Related]
18. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues.
Tel J; Hato SV; Torensma R; Buschow SI; Figdor CG; Lesterhuis WJ; de Vries IJ
Cancer Immunol Immunother; 2012 Jul; 61(7):1101-11. PubMed ID: 22193989
[TBL] [Abstract][Full Text] [Related]
19. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
20. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]